Mental and Behavioral Health

ADHD is an all-day affair, and treating it in an adult population can be difficult.

More and more women are being diagnosed with ADHD in adulthood. What's behind this increase?

Recent research determined the psychostimulants modafinil, atomoxetine, and guanfacine negatively impact bones.

Several drugs with novel mechanisms of action have been put on the pathway for speedier approval decisions by the FDA. Phase 2 and 3 trials are underway.

Make mental health a priority.

In a well-blinded study, researchers investigated and directly compared the acute effects of LSD and psilocybin in healthy participants.

A new—cough, cough—combination treatment for depression. Researchers performed an RCT of dextromethorphan-bupropion in major depressive disorder.

Risk of suicide attempt is higher among adults, women.

The causes of burnout in pharmacy are multifactorial. The solutions need to be as well.

What are the long term psychiatric and neuropsychiatric complications of COVID-19?

A recent review suggests that atomoxetine can reduce symptoms of anxiety in children and adolescents with ADHD.

Opioid use disorder—how can we battle the epidemic of overdoses?

Lack of blood clotting may afford some protection against common cardiovascular disease events, such as ischemic stroke.

Despite mixed data, there are some psychopharmacological options for treating PTSD.

Further evidence-based antidepressant treatments are needed for children and adolescents with depression.

Alzheimer disease psychosis treatment pimavanserin receives Complete Response Letter from the FDA.

Cardiometabolic risk factors for suicide? Researchers investigated associations between obesity/metabolic syndrome and suicidality in patients with bipolar disorder.

Survey results addressed connections between migraine and mental health, stigma, and treatment preferences.

Positive results from the phase 3 trial of AD04 show a 79% reduction in heavy drinking.

Adjunctive metformin in bipolar disorder. Researchers performed a randomized clinical trial of treating insulin resistance to improve clinical outcomes in treatment-resistant bipolar depression.

Axsome Therapeutics announced the robust antidepressant efficacy demonstrated in this latest study.

Medical staff, pushed past their breaking point, say something has to change.

New research presented at the 2022 American Psychiatric Association Annual Meeting evaluated program to help address the opioid epidemic.

The approval makes the drug the first novel nonstimulant ADHD therapy approved in the last 20 years.

Up to 20% of patients with bipolar disorder have 4 or more medications, so it is important to be aware of these common drug-drug interactions.